Arcutis Launches ZORYVE(R) (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 GlobeNewswire October 30, 2025 Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can be […]

(NasdaqGM:URGN), PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The

SONORO GOLD COMPLETES FINAL CONCESSION PAYMENT AND PROVIDES CORPORATE UPDATE GlobeNewswire October 30, 2025 VANCOUVER, Canada, Oct. 30, 2025 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the Company has made the final concession payment on its flagship Cerro Caliche gold

(NASDAQ:PCRX), BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025.

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups GlobeNewswire October 30, 2025 NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of

(Madrid:ORY.MC),(Boerse Stuttgart – Freiverkehr:ORN),(Madrid:ORY),(Boerse Stuttgart – Freiverkehr:ORN.SG), MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna,

Rick Sherlund, Wall Street Legend, joins in Partnership with Wedbush Tech Investment Banking GlobeNewswire October 30, 2025 SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Wedbush Securities, a full-service financial services firm, today announced that Richard “Rick” Sherlund, one of Wall Street's most respected technology bankers and research analysts, and his team at Sherlund Partners

— Posters will review product characterization and manufacturing data on T-knife's lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 — PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries,

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care GlobeNewswire October 30, 2025 FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established

(NASDAQ:MCHP), CHANDLER, Ariz., Oct. 30, 2025 (GLOBE NEWSWIRE) — The rise of smart factories, remote monitoring and connected infrastructure are increasing the demand for advanced networking systems that can operate over long distances and in challenging environments. To address the need for reliable and secure connectivity solutions, Microchip Technology (Nasdaq: MCHP) today announces its new